Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience
- 1 March 2013
- journal article
- Published by Taylor & Francis in mAbs
- Vol. 5 (2) , 202-207
Abstract
Brain tumors are a major cause of cancer-related mortality in children. Overexpression of epidermal growth factor receptor (EGFR) is detected in pediatric brain tumors and receptor density appears to increase with tumor grading. Nimotuzumab is an IgG1 antibody that targets EGFR. Twenty-three children with high-grade glioma (HGG) were enrolled in an expanded access program in which nimotuzumab was administered alone or with radio-chemotherapy. The mean number of doses was 39. Nimotuzumab was well-tolerated and treatment with the antibody yielded a survival benefit: median survival time was 32.66 mo and the 2-y survival rate was 54.2%. This study demonstrated the feasibility of prolonged administration of nimotuzumab and showed preliminary evidence of clinical benefit in HGG patients with poor prognosis.Keywords
This publication has 28 references indexed in Scilit:
- Brain Tumors in Children- Current Therapies and Newer DirectionsIndian Journal of Pediatrics, 2012
- EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell LinesClinical Cancer Research, 2009
- Pediatric glioblastomas: A histopathological and molecular genetic studyNeuro-Oncology, 2009
- [Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them].2008
- Chemotherapy for Malignant Brain Tumors of ChildhoodJournal of Child Neurology, 2008
- Tyrosine kinase expression in pediatric high grade astrocytomaJournal of Neuro-Oncology, 2008
- Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trialCancer Biology & Therapy, 2006
- Diffuse brainstem glioma in children: critical review of clinical trialsThe Lancet Oncology, 2006
- Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody Against Epidermal Growth Factor Receptor in Advanced Brain Tumor Patients: Preliminary StudyHybridoma, 2001
- Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.1999